Question explored with the scientific record
Hydroxychloroquine dangerous or not
The short version: for hospitalized COVID-19 patients, hydroxychloroquine adds harm without benefit; for early outpatient use, the evidence is too weak to call.
The strongest evidence comes from a meta-analysis of 11 randomized trials in hospitalized patients. Adding hydroxychloroquine to standard care did not reduce mortality (RR 1.13, 95% CI 0.99–1.27, p=0.06) or shorten hospital stay, but it did increase adverse events by 81% (RR 1.81, p<0.05) [2]. A separate retrospective cohort of 734 matched patients found no mortality difference (OR 0.95, 95% CI 0.62–1.46) and no excess arrhythmia signal (OR 0.98) [3]. One Spanish observational study of 2,075 patients reported a mortality benefit (adjusted OR 0.39–0.45) [4], but observational studies are far weaker than randomized ones—confounding by indication is a known problem.
The outpatient evidence is all non-randomized. A 42-patient French study showed faster viral clearance with HCQ plus azithromycin [5], and a Brazilian series of 636 patients reported lower hospitalization rates (1.2% vs 5.4%) [5]. But without randomization, these comparisons are unreliable. The long-term retinal toxicity risk is real: cumulative doses above 1 kg can cause permanent vision damage, even years after stopping [6, 8].
| Population | Outcome | HCQ result | Comparator result |
|---|---|---|---|
| Hospitalized (11 RCTs) | Mortality | RR 1.13 (0.99–1.27) | Standard care |
| Hospitalized (matched cohort) | Mortality | 13.1% | 13.6% |
| Hospitalized (matched cohort) | Mortality/arrhythmia | 17.4% | 17.7% |
| Outpatients (non-randomized) | Hospitalization | 1.2% (treated early) | 5.4% (declined) |
My call: for hospitalized COVID-19 patients, hydroxychloroquine is not worth the risk—no benefit and more harm. For early outpatient use, the evidence is not clear; the studies are too weak to support a recommendation. Confidence: moderate for the hospitalized finding, low for the outpatient claim.
Sources examined 8
-
Low voltage areas defragmentation in sinus rhythm for radiofrequency ablation of persistent atrial fibrillation (SCAR-AF Study)
Close ECG monitoring in hospitalized COVID-19 patients treated with hydroxychloroquine and azithromycin showed modest QTc prolongation with rare therapy interruption; a separate multicenter SCAR-AF trial investigates defragmentation of low voltage atrial areas during persistent …
DOI: 10.1016/j.acvdsp.2020.10.230 -
Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials
A meta-analysis of 11 randomized controlled trials found that adding hydroxychloroquine to standard care for hospitalized COVID-19 patients provides no significant benefit in reducing mortality, PCR negativity, hospital stay, or other outcomes, but increases adverse events.
DOI: 10.1038/s41598-021-91089-3 -
Hydroxychloroquine in Hospitalized Patients with COVID‐19: Real‐World Experience Assessing Mortality
A retrospective multinational cohort study found no significant association between hydroxychloroquine (with or without azithromycin) and 30-day mortality or mortality/arrhythmia in hospitalized COVID-19 patients after propensity matching.
DOI: 10.1002/phar.2467 -
The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients
In this observational study of 2,075 hospitalized COVID-19 patients across 17 Spanish hospitals, hydroxychloroquine treatment was significantly associated with lower hospital mortality in all four multivariable logistic regression models (adjusted OR 0.39–0.45, all p<0.001), wit…
DOI: 10.1007/s11739-020-02505-x -
Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis
This review argues that hydroxychloroquine plus azithromycin or doxycycline, preferably with zinc, is safe and effective as early outpatient treatment for high-risk COVID-19 patients, citing non-randomized and observational evidence to prevent hospitalization.
DOI: 10.1093/aje/kwaa093 -
Unusual Fundus Autofluorescence Appearance in a Patient with Hydroxychloroquine Retinal Toxicity
Unusual fundus autofluorescence appearance in hydroxychloroquine retinal toxicity observed in a 53-year-old woman after nine years of therapy and three years post-cessation.
DOI: 10.1159/000433417 -
THE PRESCRIBING OF CHLOROQUINE AND HYDROXYCHLOROQUINE BY CONSULTANT RHEUMATOLOGISTS IN THE UK
Hydroxychloroquine is prescribed far more often than chloroquine by UK consultant rheumatologists for rheumatoid arthritis, with most using fixed starting doses but wide variation in ophthalmologic monitoring and notable gaps in baseline eye testing and sun-protection counseling.
DOI: 10.1093/rheumatology/26.5.375 -
Early Paracentral Visual Field Loss in Patients Taking Hydroxychloroquine
This retrospective study of 262 hydroxychloroquine users attending a New Zealand ophthalmic screening program found a small number with reproducible visual field defects, suggesting toxicity can occur even at doses below 6.5 mg/kg/day and in patients with normal renal function, …
DOI: 10.1001/archopht.124.12.1729